{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:31:01Z","timestamp":1785306661682,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.carrev.2024.07.002","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T16:40:55Z","timestamp":1720284055000},"page":"71-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The impact of elevated C-reactive protein levels on long-term outcomes of patients undergoing transcatheter aortic valve replacement"],"prefix":"10.1016","volume":"70","author":[{"given":"Stephanie","family":"Brunner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Moccetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucca","family":"Loretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Attinger-Toller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Kurmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florim","family":"Cuculi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Wolfrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Toggweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.carrev.2024.07.002_bb0005","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/ejcts\/ezab389","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"60","author":"Vahanian","year":"2021","journal-title":"Eur J Cardiothorac Surg"},{"issue":"30","key":"10.1016\/j.carrev.2024.07.002_bb0010","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1093\/eurheartj\/ehab375","article-title":"Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement","volume":"42","author":"Jorgensen","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.carrev.2024.07.002_bb0015","first-page":"639","article-title":"One-year observation of inflammatory markers in patients with aortic valve stenosis","volume":"20","author":"Swierszcz","year":"2011","journal-title":"J Heart Valve Dis"},{"issue":"3","key":"10.1016\/j.carrev.2024.07.002_bb0020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/14017431.2016.1151928","article-title":"Increased hsCRP is associated with higher risk of aortic valve replacement in patients with aortic stenosis","volume":"50","author":"Blyme","year":"2016","journal-title":"Scand Cardiovasc J"},{"issue":"5","key":"10.1016\/j.carrev.2024.07.002_bb0025","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2174\/0929867324666170727110241","article-title":"Biomarkers in aortic valve stenosis and their clinical significance in Transcatheter aortic valve implantation","volume":"26","author":"Toutouzas","year":"2019","journal-title":"Curr Med Chem"},{"issue":"4","key":"10.1016\/j.carrev.2024.07.002_bb0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0002-8703(56)90099-0","article-title":"A study of C-reactive protein in the serum of patients with congestive heart failure","volume":"51","author":"Elster","year":"1956","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.carrev.2024.07.002_bb0035","article-title":"Elevated fasting glucose and C-reactive protein levels predict increased all-cause mortality after elective Transcatheter aortic valve implantation","volume":"13","author":"Dekany","year":"2022","journal-title":"Life (Basel)"},{"issue":"5","key":"10.1016\/j.carrev.2024.07.002_bb0040","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/jocs.14499","article-title":"Prognostic impact of baseline C-reactive protein levels on mortality after transcatheter aortic valve implantation","volume":"35","author":"Takagi","year":"2020","journal-title":"J Card Surg"},{"issue":"6","key":"10.1016\/j.carrev.2024.07.002_bb0045","doi-asserted-by":"crossref","first-page":"629","DOI":"10.4244\/EIJ-D-18-00059","article-title":"Combination of high-sensitivity C-reactive protein with logistic EuroSCORE improves risk stratification in patients undergoing TAVI","volume":"14","author":"Stundl","year":"2018","journal-title":"EuroIntervention"},{"issue":"2","key":"10.1016\/j.carrev.2024.07.002_bb0050","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.amjcard.2018.04.005","article-title":"Effect of serum C-reactive protein level on admission to predict mortality after Transcatheter aortic valve implantation","volume":"122","author":"Hioki","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.carrev.2024.07.002_bb0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.amjcard.2020.03.037","article-title":"Additive value of high-density lipoprotein cholesterol and C-reactive protein level assessment for prediction of 2-year mortality after Transcatheter aortic valve implantation","volume":"126","author":"Zielinski","year":"2020","journal-title":"Am J Cardiol"},{"issue":"21","key":"10.1016\/j.carrev.2024.07.002_bb0060","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.jacc.2021.02.038","article-title":"Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research","volume":"77","author":"Varc-3 Writing C, Genereux P, Piazza N, Alu MC, Nazif T, Hahn RT","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.carrev.2024.07.002_bb0065","first-page":"1285","article-title":"Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome","volume":"38","author":"Tarantini","year":"2017","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.carrev.2024.07.002_bb0070","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.amjcard.2016.02.040","article-title":"Impact of diabetes mellitus on outcomes after Transcatheter aortic valve implantation","volume":"117","author":"Abramowitz","year":"2016","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.carrev.2024.07.002_bb0075","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10554-015-0651-9","article-title":"Incidence and severity of atherosclerotic cardiovascular artery disease in patients undergoing TAVI","volume":"31","author":"Fusini","year":"2015","journal-title":"Int J Card Imaging"},{"issue":"2","key":"10.1016\/j.carrev.2024.07.002_bb0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.hlc.2020.09.003","article-title":"Combating inflammation in cardiovascular disease","volume":"30","author":"Sethwala","year":"2021","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.carrev.2024.07.002_bb0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting residual inflammatory Risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"25","key":"10.1016\/j.carrev.2024.07.002_bb0090","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa040967","article-title":"Inflammatory markers and the risk of coronary heart disease in men and women","volume":"351","author":"Pai","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.carrev.2024.07.002_bb0095","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1161\/CIRCULATIONAHA.106.649939","article-title":"Prognostic significance of the centers for disease control\/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease","volume":"115","author":"Sabatine","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.carrev.2024.07.002_bb0100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejvs.2017.05.009","article-title":"Systematic review and Meta-analysis of the association between C-reactive protein and major cardiovascular events in patients with peripheral artery disease","volume":"54","author":"Singh","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"9050","key":"10.1016\/j.carrev.2024.07.002_bb0105","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0140-6736(96)07591-5","article-title":"Production of C-reactive protein and risk of coronary events in stable and unstable angina. European concerted action on thrombosis and disabilities angina pectoris study group","volume":"349","author":"Haverkate","year":"1997","journal-title":"Lancet"},{"issue":"9709","key":"10.1016\/j.carrev.2024.07.002_bb0110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Emerging Risk Factors","year":"2010","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.carrev.2024.07.002_bb0115","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Emerging Risk Factors","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.carrev.2024.07.002_bb0120","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A test in context: high-sensitivity C-reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.carrev.2024.07.002_bb0125","first-page":"225","article-title":"Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein","volume":"75","author":"Moutachakkir","year":"2017","journal-title":"Ann Biol Clin (Paris)"},{"issue":"3","key":"10.1016\/j.carrev.2024.07.002_bb0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cger.2017.02.002","article-title":"Frailty in older persons","volume":"33","author":"Cesari","year":"2017","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"10.1016\/j.carrev.2024.07.002_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2010.08.009","article-title":"The frailty syndrome: definition and natural history","volume":"27","author":"Xue","year":"2011","journal-title":"Clin Geriatr Med"},{"issue":"9","key":"10.1016\/j.carrev.2024.07.002_bb0140","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","article-title":"Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty","volume":"15","author":"Ferrucci","year":"2018","journal-title":"Nat Rev Cardiol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838924005797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838924005797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:26:37Z","timestamp":1738887997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838924005797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"alternative-id":["S1553838924005797"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2024.07.002","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of elevated C-reactive protein levels on long-term outcomes of patients undergoing transcatheter aortic valve replacement","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2024.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}